Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.
作者信息
Yang Alexander, Cannataro Vincent L, Townsend Jeffrey P
机构信息
Yale School of Medicine, New Haven, CT, USA.
Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
出版信息
Eur Urol. 2020 Jan;77(1):e24-e25. doi: 10.1016/j.eururo.2019.08.018. Epub 2019 Aug 30.
Abstract
摘要
相似文献
1
Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.回复：施明君、孟祥宇、菲利普·拉米等人。载脂蛋白B编辑酶催化多肽样蛋白介导的诱变可能是膀胱癌中FGFR3 S249C突变过度表达的原因。《欧洲泌尿外科杂志》2019年；76卷：第9 - 13页。
Eur Urol. 2020 Jan;77(1):e24-e25. doi: 10.1016/j.eururo.2019.08.018. Epub 2019 Aug 30.
2
Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13.对亚历山大·杨、文森特·L·卡纳塔罗、杰弗里·P·汤森德致编辑的信的回复，主题：施明君、孟祥宇、菲利普·拉米等人。载脂蛋白B编辑复合体介导的诱变可能是膀胱癌中FGFR3 S249C突变过度表达的原因。《欧洲泌尿外科杂志》2019年，76卷：9 - 13页
Eur Urol. 2020 Jan;77(1):e26-e27. doi: 10.1016/j.eururo.2019.08.012. Epub 2019 Sep 5.
3
APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.载脂蛋白 B mRNA 编辑酶催化多肽 3 介导的突变作为膀胱癌中 FGFR3 S249C 突变过度表达的可能原因。
Eur Urol. 2019 Jul;76(1):9-13. doi: 10.1016/j.eururo.2019.03.032. Epub 2019 Apr 8.
4
Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.膀胱癌中成纤维细胞生长因子受体3基因（FGFR3）A248C、S249C、G372C和T375C突变的发生率。
Genet Mol Res. 2011 Jan 18;10(1):86-95. doi: 10.4238/vol10-1gmr923.
5
Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15: Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer.回复：明·阮·蒂奥、何塞·毛里西奥·莫塔、卡丽莎·A·怀廷等。成纤维细胞生长因子受体3改变状态与局部晚期和转移性尿路上皮癌对铂类化疗的不同敏感性相关。《欧洲泌尿外科杂志》2020年；78卷：907 - 15页：将FGFR3突变状态和管腔乳头状亚型与膀胱癌对顺铂化疗的反应联系起来。
Eur Urol. 2021 Jun;79(6):e182-e183. doi: 10.1016/j.eururo.2021.03.028. Epub 2021 Apr 8.
6
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.通过短发夹RNA（shRNA）敲低技术确定S249C突变型成纤维细胞生长因子受体3（FGFR3）是膀胱癌的一个潜在治疗靶点。
Oncogene. 2007 Aug 30;26(40):5889-99. doi: 10.1038/sj.onc.1210399. Epub 2007 Mar 26.
7
FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.在约旦人群中膀胱癌患者的 FGFR3 突变状态和蛋白表达。
Cancer Epidemiol. 2010 Dec;34(6):724-32. doi: 10.1016/j.canep.2010.05.003. Epub 2010 Jun 9.
8
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.HS3ST2、SEPTIN9和SLIT2的启动子高甲基化联合FGFR3突变作为一种灵敏/特异的尿液检测方法，用于低危或高危非肌层浸润性膀胱癌患者的诊断和监测。
BMC Cancer. 2016 Sep 1;16(1):704. doi: 10.1186/s12885-016-2748-5.
9
Re: Mutations in TERT Promoter and FGFR3 and Telomere Length in Bladder Cancer.
J Urol. 2016 Apr;195(4 Pt 1):1168-9. doi: 10.1016/j.juro.2016.01.020. Epub 2016 Jan 21.
引用本文的文献
1
Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.鉴定膀胱癌中 APOBEC 诱导热点突变中新的驱动和乘客突变。
Genome Med. 2020 Sep 28;12(1):85. doi: 10.1186/s13073-020-00781-y.
2
Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers.尿路上皮膀胱癌中的非编码突变：生物学和临床相关性以及作为生物标志物的潜在用途
Bladder Cancer. 2020 Jun 11;6(2):211-213. doi: 10.3233/BLC-200278.
本文引用的文献
1
Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.由 APOBEC3A 和中尺度基因组特征驱动的癌症中的乘客热点突变。
Science. 2019 Jun 28;364(6447). doi: 10.1126/science.aaw2872.
2
APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.载脂蛋白 B mRNA 编辑酶催化多肽 3 介导的突变作为膀胱癌中 FGFR3 S249C 突变过度表达的可能原因。
Eur Urol. 2019 Jul;76(1):9-13. doi: 10.1016/j.eururo.2019.03.032. Epub 2019 Apr 8.
3
Effect Sizes of Somatic Mutations in Cancer.癌症体细胞突变的效应大小。
J Natl Cancer Inst. 2018 Nov 1;110(11):1171-1177. doi: 10.1093/jnci/djy168.
4
Universal Patterns of Selection in Cancer and Somatic Tissues.癌症和体细胞组织中的普遍选择模式。
Cell. 2018 Jun 14;173(7):1823. doi: 10.1016/j.cell.2018.06.001.
5
DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution.DeconstructSigs：剖析单个肿瘤中的突变过程可区分DNA修复缺陷和癌演变模式。
Genome Biol. 2016 Feb 22;17:31. doi: 10.1186/s13059-016-0893-4.
Zotero 插件